The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Immune signalling pathways convert pathogenic stimuli into cytosolic events that lead to the
resolution of infection. Upon ligand engagement, immune receptors together with their …

Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune
responses. Tumor escape associated with low target antigen expression is emerging as one …

Pediatric cancers often mimic fetal tissues and express proteins normally silenced
postnatally that could serve as immune targets. We developed T cells expressing chimeric …

As the targets of chimeric antigen receptor (CAR)–T cells expand to a variety of cancers,
autoimmune diseases, viral infections, and fibrosis, there is an increasing demand for …

Chimeric antigen receptor (CAR) T cell therapy has attracted attention for its promising
therapeutic effects on hematological malignancies. However, there are problems such as …

The immunological synapse is a molecular hub that facilitates the delivery of three activation
signals, namely antigen, costimulation/corepression and cytokines, from antigen-presenting …

CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL.
However, CD19 loss is a frequent cause of relapse. Simultaneously targeting a second …

The exploitation of T cell-based immunotherapies and immune checkpoint blockade for
cancer treatment has dramatically shifted oncological treatment paradigms and broadened …

The T cell receptor (TCR) pathway receives, processes, and amplifies the signal from
pathogenic antigens to the activation of T cells. Although major components in this pathway …